DDrare: Database of Drug Development for Rare Diseases

283. 後天性赤芽球癆
［臨床試験数：17，薬物数：36（DrugBank：19），標的遺伝子数：16，標的パスウェイ数：91］

Searched query = "Acquired pure red cell aplasia", "Pure red cell aplasia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AF37702 Injection; AF37702, Hematide; Alemtuzumab; Anti-thymocyte globulin; Bortezomib; Bortezomib/dexamethasone; Campath; Campath, Chemo and/or TBI Allo SCT; Cyclophosphamide; Cyclophosphamide + pred; Cyclosporine; Cyclosporine A; Cyclosporine combine with mycophenolate mofetil; Daclizumab; Dexamethasone; Filgrastim; Fludarabine; Fludarabine Phosphate; Hematide; Hematide, peginesatide; Leucine; Methylprednisolone; Mycophenolate; Mycophenolate mofetil; Other: Laboratory Biomarker Analysis; Peginesatide; Phosphate; Prednisone; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Peripheral Blood Stem Cell Transplantation; Radiation: Total Body Irradiation; Radiation: Total-Body Irradiation; Rituximab; Sirolimus; Tacrolimus; Trifluoperazine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03918265 (ClinicalTrials.gov)	May 4, 2019	16/4/2019	Tacrolimus Treatment for Refractory Autoimmune Cytopenia	Tacrolimus Treatment for Refractory Autoimmune Cytopenia	Autoimmune Hemolytic Anemia;Pure Red Cell Aplasia;Evans Syndrome	Drug: Tacrolimus	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	80 Years	All	80	Phase 4	China
2	NCT03540472 (ClinicalTrials.gov)	June 10, 2018	14/5/2018	Tacrolimus Treatment for Refractory PRCA	Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study	Pure Red Cell Aplasia	Drug: tacrolimus	Peking Union Medical College Hospital	NULL	Unknown status	18 Years	80 Years	All	30	Phase 4	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03918265
(ClinicalTrials.gov)

May 4, 2019

16/4/2019

Tacrolimus Treatment for Refractory Autoimmune Cytopenia

Autoimmune Hemolytic Anemia;Pure Red Cell Aplasia;Evans Syndrome

Drug: Tacrolimus

Peking Union Medical College Hospital

NULL

Recruiting

18 Years

80 Years

All

Phase 4

China

NCT03540472
(ClinicalTrials.gov)

June 10, 2018

14/5/2018

Tacrolimus Treatment for Refractory PRCA

Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study

Pure Red Cell Aplasia

Drug: tacrolimus